Clinical Trial Update: Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

View source ↗

Summary

An AstraZeneca-sponsored clinical trial update documents a risk of hospitalization for severe hypersensitivity reactions, including severe skin reactions, in pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED